Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism by 源�蹂묐え
 International Journal of 
Molecular Sciences
Article
Emodin Sensitizes Hepatocellular Carcinoma Cells to
the Anti-Cancer Effect of Sorafenib through
Suppression of Cholesterol Metabolism
Young-Seon Kim 1,†, Yoon-Mi Lee 2,†, Taek-In Oh 1, Dong Hoon Shin 3, Geon-Hee Kim 1,
Sang-Yeon Kan 1, Hyeji Kang 1, Ji Hyung Kim 4, Byeong Mo Kim 5 , Woo Jong Yim 6 and
Ji-Hong Lim 1,7,*
1 Department of Biomedical Chemistry, College of Biomedical & Health Science, Konkuk University,
Chungju 27478, Chungbuk, Korea; yskim0801@kku.ac.kr (Y.-S.K.); dk1050@kku.ac.kr (T.-I.O.);
rlarjsgml4@kku.ac.kr (G.-H.K.); hsb6477@kku.ac.kr (S.-Y.K.); kkang@kku.ac.kr (H.K.)
2 Department of Food Bioscience, College of Biomedical & Health Science, Konkuk University,
Chungju 27478, Chungbuk, Korea; yoonmilee@kku.ac.kr
3 Research Institute, National Cancer Center, Department of Cancer Biomedical Science, National Cancer
Center Graduate School of Cancer Science and Policy, Goyang 10408, Korea; dhshin@ncc.re.kr
4 College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea; jay_kim@korea.ac.kr
5 Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases (SIRIC), Yonsei University
College of Medicine, Seodaemun-gu, Seoul 03722, Korea; bkim2@yuhs.ac
6 Jung-Ang Microbe Research Institute (JM), 398, Jikji-daero, Heungdeok-gu, Cheongju 28576, Chungbuk,
Korea; ywj0808@naver.com
7 Diabetes and Bio-Research Center, Konkuk University, Chungju 27478, Chungbuk, Korea
* Correspondence: jhlim@kku.ac.kr; Fax: +82-43-840-3929; Tel.: +82-43-840-3567
† These authors contributed equally.
Received: 4 September 2018; Accepted: 10 October 2018; Published: 12 October 2018


Abstract: Reduced therapeutic efficacy of sorafenib, a first-generation multikinase inhibitor, is often
observed during the treatment of advanced hepatocellular carcinoma (HCC). Emodin is an active
component of Chinese herbs, and is effective against leukemia, lung cancer, colon cancer, pancreatic
cancer, and HCC; however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not
been evaluated. Here, we demonstrate that emodin significantly improved the anti-cancer effect of
sorafenib in HCC cells, such as HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Mechanistically,
emodin inhibits sterol regulatory element-binding protein-2 (SREBP-2) transcriptional activity, which
suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signaling. Additionally,
attenuated cholesterol synthesis and oncogenic AKT signaling inactivated signal transducer and
activator of transcription 3 (STAT3), an oncogenic transcription factor. Furthermore, emodin
synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence
of sorafenib. Animal models xenografted with HepG2 or SK-HEP-1 cells also showed that the
combination of emodin and sorafenib was sufficient to inhibit tumor growth. Overall, these results
suggested that the combination of emodin and sorafenib may offer a potential therapy for patients
with advanced HCC.
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1. Introduction
Hepatocellular carcinoma (HCC), which is closely associated with chronic liver diseases,
particularly viral hepatitis and metabolic steatohepatitis, is the third most common cause of
cancer-related deaths worldwide [1,2]. Sorafenib, as a small-molecule inhibitor that targets multiple
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types of kinases required for tumor growth, angiogenesis, and metastasis, has been used as the only
standard treatment available for advanced HCC [1]. However, a previous clinical study in patients
with advanced HCC showed that the median overall survival was improved by only a few months
in the sorafenib group compared with that in the placebo group, which implied that there were no
significant differences between the groups [3]. Thus, drugs that can sensitize the anti-cancer efficacy of
sorafenib would confer beneficial effects on HCC treatment.
Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is an active compound predominantly found
in the rhizome of Rheum palmatum L. [4]. Many types of biologically active compounds that are used
widely for cancer treatment, such as doxorubicin and paclitaxel, are derived from nature. Similarly,
recent studies have shown that emodin also has anti-cancer effects in different types of cancers,
including leukemia, lung cancer, colon cancer, gallbladder cancer, pancreatic cancer, breast cancer, and
HCC [5,6]. Mechanistically, emodin suppresses cell growth and proliferation through the attenuation
of oncogenic growth signaling, such as Wnt/β-catenin, HER-2 tyrosine kinase, mitogen-activated
protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (AKT), which leads
to apoptosis in several cancer cell types [7–9]. Interestingly, several recent studies have shown that
emodin could synergistically improve the anti-cancer efficacy of conventional chemotherapeutic drugs,
such as gemcitabine, paclitaxel, cisplatin, and etoposide, in pancreatic cancer, malignant melanoma,
and HER-2/neu-overexpressing lung cancer [10–13]. Nevertheless, the ability of emodin to sensitize
cells to the anti-cancer efficacy of molecular targeted cancer therapies, such as sorafenib, has not been
investigated in HCC. Thus, we have investigated whether emodin exerted beneficial effects to improve
the anti-cancer efficacy of sorafenib in HCC therapy.
Anabolic metabolism, including cholesterol biosynthesis, which is also called cholesterogenesis,
is considered to be a hallmark of cancer [14]. Evidence has emerged to indicate that the biosynthesis
of fatty acids and cholesterol is essential for the development and progression of a wide variety of
tumors, owing to their critical nature as building blocks for membrane components [15]. In addition,
increased intracellular cholesterol levels were closely associated with the subsequent alterations
of oncogenic growth signaling and motility in cancer cells [14]. Intracellular cholesterol levels are
mainly controlled by sterol regulatory element-binding protein-2 (SREBP-2), a transcription factor that
regulates genes encoding a variety of enzymes required for cholesterogenesis [16]. Mechanistically,
SREBP-2 transcriptionally activates the expression of cholesterogenic genes in cholesterol-depleted
conditions, such as hydroxymethylglutaryl (HMG)-CoA synthase 1 (HMGCS1), HMG-CoA reductase
(HMGCR), farnesyl diphosphate synthase (FDPS), and mevalonate diphosphate decarboxylase
(MVD) [16]. Although the cholesterogenic pathway is considered to be a promising pharmaceutical
target for cancer treatment, the ability to sensitize HCC cells to the effect of cholesterol-lowering drugs
and improve the anti-cancer effect has been poorly studied.
We hypothesized that the combination of emodin and sorafenib would lead to synergistic
anti-cancer efficacy of HCC therapy. In the present study, we have shown that the combination
of emodin and sorafenib functioned synergistically to increase cell cycle arrest and the proportion
of apoptotic cells, which was consistent with the observed decrease in cell viability, through
the suppression of oncogenic AKT signaling and activation of signal transducer and activator of
transcription 3 (STAT3) in HCC cells. We also found that the cholesterol-lowering effect of emodin,
mediated through the suppression of SREBP-2 transcriptional activity and its target gene expression,
was involved in the combined anti-cancer efficacy with sorafenib. Moreover, we suggested that
the combination treatment of both emodin and sorafenib would act synergistically to produce a
more effective anti-cancer effect in HepG2 and SK-HEP-1 cell-transplanted xenograft models than
monotherapy with sorafenib. Overall, our results have demonstrated that the combination of emodin
and sorafenib may be a promising strategy to achieve improvements in the therapeutic efficacy of
sorafenib in patients with advanced HCC.
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2. Results
2.1. Synergistic Anti-Cancer Effect of Combination of Emodin and Sorafenib in HCC Cells
Emodin, a bioactive compound found in many species of plants, including rhubarb and buckthorn,
has been shown to have anti-cancer effects in multiple types of cancer; however, its ability to sensitize
HCC cells to the anti-cancer efficacy on sorafenib therapy has been not elucidated. Here, we first
evaluated the sensitizing efficacy of emodin on the growth inhibition of HCC cells induced by 2 µM of
sorafenib. The treatment with 20 µM of emodin strongly enhanced the suppressive effect of sorafenib
on HCC cell growth in a time-dependent manner (Figure 1A,B). To elucidate whether emodin was
sufficient to enhance the anti-cancer activity of lower concentrations of sorafenib, the cell viability
was measured after the treatment with 20 µM emodin and different concentrations of sorafenib.
Unexpectedly, the sensitizing anti-cancer effect of 20 µM emodin was observed to occur with 0.5 µM
and 1 µM sorafenib treatment in Hep3B and Huh7 cells (Figure 1C). In addition, Figure 1C also shows
that when HCC cells are exposed to higher concentration of sorafenib than 2 µM with 20 µM of emodin,
sensitizing anti-cancer effects induced by combination of both drugs were not observed (Figure 1C).
These results suggest that emodin could increase the anti-cancer activity upon lower concentration
of sorafenib.
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Figure 1. Emodin sensitizes hepatocellular carcinoma (HCC) cells to the anti-cancer effect of sorafenib.
(A) Cell viability analysis after emodin, sorafenib, or the combination treatment of both drugs in five
HCC cell lines. The cells were incubated with emodin (20 µM), sorafenib (2 µM), or the combination
(20 µM emodin and 2 µM sorafenib) for 24, 48, or 72 h, as indicated. The values represent the mean ±
SEM of three independent experiments performed in triplicate; * p < 0.05, ** p < 0.01, and *** p < 0.001.
(B) Images of crystal violet staining. (C) The cell viability after different concentrations of sorafenib
(0.5, 1, 2, 5, and 10 µM) with 20 µM emodin in Hep3B, HepG2, and Huh7 cells. The values represent
the mean ± SEM of three independent experiments performed in triplicate; * p < 0.05 and ** p < 0.01.
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2.2. Emodin Did Not Sensitize HCC to the Anti-Cancer Activity of Doxorubicin or 5-Fluorouracil
Doxorubicin and 5-fluorouracil are two of the first-line chemotherapeutic drugs used for HCC
treatment [1]. To investigate the specificity of emodin to sensitize HCC cells to the anti-cancer effects of
sorafenib, the efficiency of the combination of emodin was tested with these standard chemotherapeutic
drugs. However, emodin did not exert synergistic anti-cancer effects when combined with doxorubicin
(Figure 2A) or 5-fluorouracil (Figure 2B) treatment.
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Figure 2. Emodin did not sensitize HCC to the anti-cancer effect of doxorubicin or 5-fluorouracil.
(A) The viability of three HCC cell lines after treatment with of emodin and doxorubicin. (B) The
combinatory anti-cancer effect of emodin and 5-fluorouracil in the HCC cell lines. Cells were treated
with the indicated drugs (1 µM doxorubicin or 10 µM 5-fluorouracil) for 48 h in the absence or presence
of 20 µM emodin. The values are presented as the mean ± SEM of three independent experiments
performed in duplicate; * p < 0.05 and ** p < 0.01.
2.3. Combination Therapy of Emodin and Sorafenib Caused Cell Cycle Arrest and Apoptosis in HCC Cells
As sorafenib suppressed tumor growth through cell cycle arrest and apoptosis [17], we
investigated whether emodin sensitized HCC cells to t e antipro iferative pro-ap ptotic effects
of sorafenib. Cell cycle arrest of the G1 phase of approximately 15% was observed after reatment
with th combination of emodin and sorafenib; however, treatment with a single compound did not
alter ell cycle distributi n in HepG2 c lls (Figur 3A). The combination of emodin and sorafe ib
consist ntly induced G1 phase arrest in four diffe nt HCC cell lines (Figur 3B). When cell cycle
arrest in he G1 phase occurs, the c lls cease DNA plication and proliferation to maintain genomic
stability [18]. The combination of emodin and soraf nib significantly incre sed the Ki67-negative cell
population but decreased he Ki67-p s tive cell population, which indicated that the combination of
emodin a d sorafenib suppressed cell proliferation (Figure 3C). As prolonged cell cycle arrest and
suppressed pr liferation led to apoptosis [18], the pro-apoptotic efficacy of combination tre tments of
emodin and soraf nib was evaluated. Treatment with 2 µM s raf nib or 20 µM emodin resulted i a
slight (approximately 8%) incre se in apoptosis; ho ever, the combination therapy with both drugs
strongly increased the apoptoti cell population, by approximat ly 55% (Figure 3D). These results
indicated that emodin synergistically enhanced the nti-cancer efficacy of sorafenib through effects on
the cell cycle progression and apoptosis.
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expression and cholesterogenesis in HCC cells. Simvastatin-induced luciferase activity of steroid 
response element (SRE) was attenuated by emodin in a dose-dependent manner in wild-type (SRE–
Luc–WT) cells, but not in mutant (SRE–Luc–Mut) luciferase vector-expressing cells, which suggested 
that emodin may inhibit SREBP-2 transcriptional activity (Figure 4A). Similarly, the induction of 
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Figure 3. The combination therapy of emodin and sorafenib causes cell cycle arrest and apoptosis in
HCC cells. (A) The cell cycle analysis after treatment with the combination of emodin and sorafenib in
HepG2 cells. (B) The cell cycle analysis after treatment with the combination of emodin and sorafenib
in Hep3B, Huh7, SK- EP-1, and PLC/PRF5 cells. The cells were incubated with emodin (20 µM),
sorafenib (2 µM), or the combination (20 µM emodin and 2 µM sorafenib) for 16 h. The values represent
the mean ± SEM of three independent experiments performed in duplicate. (C) Cell proliferation after
treatment with the combination of emodin and sorafenib in five HCC cell lines. The cells were treated
with the indicated drugs for 24 h prior to analysis. The values represent the mean ± SEM of three
independent experiments performed in duplicate. (D) The induction of apoptosis after treatment with
the combination of emodin and sorafenib in HepG2 cells. The cells were incubated with emodin and
sorafenib for 72 h. The values represent the mean ± SEM of three independent experiments performed
in duplicate; * p < 0.05 and ** p < 0.01.
2.4. Emodin Suppressed Cholesterogenic Gene Expression and Intracellular Cholesterol Levels through the
Attenuation of SREBP-2 in HCC Cells
Previously, the cholesterol-lowering effect of emodin through the suppression of
cholesterogenic gene expression, such as 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1),
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and farnesyl pyrophosphate synthase (FDPS),
has been reported in a high fat diet-induced obese mice model [19]. Cholesterogenic gene expression
is tightly regulated through SREBP-2 translocation into the nucleus and transcriptional activation
upon decreased intracellular cholesterol [16]. Because cholesterogenesis is an essential anabolic
process to provide lipid building block components for the cellular membrane during cancer cell
growth [14], we observed whether emodin also suppresses cholesterogenic gene expression and
cholesterogenesis in HCC cells. Simvastatin-induced luciferase activity of steroid response element
(SRE) was attenuated by emodin in a dose-dependent manner in wild-type (SRE–Luc–WT) cells,
but not in mutant (SRE–Luc–Mut) luciferase vector-expressing cells, which suggested that emodin
may inhibit SREBP-2 transcriptional activity (Figure 4A). Similarly, the induction of SREBP-2 target
cholesterogenic genes, such as HMGCS1, HMGCR, mevalonate diphosphate decarboxylase (MVD),
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FDPS, and 7-dehydrocholesterol reductase (DHCR7) expression, by simvastatin was significantly
decreased by 20 µM emodin in SK-HEP-1 (Figure 4B) and HepG2 (Figure 4C) cells. In addition, the
cholesterogenic proteins, HMGCS1, HMGCR, and FDPS, were decreased by emodin in SK-HEP-1
cells in a dose-dependent manner (Figure 4D). We subsequently observed that emodin as well as
simvastatin lowered the total intracellular cholesterol content in HepG2, SK-HEP-1, and Huh7 cells
(Figure 4E). These results revealed that emodin attenuated cholesterol biosynthesis through the
suppression of SREBP-2 transcriptional activity in HCC cells.
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Figure 4. Emodin suppresses SREBP-2 tr scri tional activity and d cr ases intracellular cholesterol.
(A) The steroid-responsive el m nt (SRE) contain g luciferase vectors (SRE– –Luc–Mut)
were transi ntly transfected into SK-HEP 1 cells. Transfect d cells wer incubate 10 or 20 µM
emodin in the absence or presence of 10 µM simvastatin for 24 h. The values represent the mean
± SD of three independent experiments performed in duplicate; * p < 0.05 and ** p < 0.01. (B) The
suppressive effect of emodin on simvastatin-induced cholesterogenic gene expression. SK-HEP-1 cells
were incubated with 20 µM emodin in the absence or presence of 10 µM simvastatin for 24 h. The
gene expression was measured by quantitative real-time PCR, and relative mRNA expression was
normalized to the expression of 36B4. The values represent the mean ± SEM of three independent
experiments performed in triplicate; * p < 0.05 and ** p < 0.01. (C) The suppressive effect of emodin
on simvastatin-induced cholesterogenic gene expression in HepG2 cells. (D) The inhibitory effect of
emodin on cholesterogenic enzyme xpressi n in SK-HEP-1 cells. The cells were incu ated with 5, 10,
20, or 40 µM emodin for 24 h, and protein expressi n was analyzed by Western blotting, as described in
the Materials and Methods. Relative protein expression levels are shown. The values are resented as
the mean ± SD of three independent experiments perfor ed; * p < 0.05 and ** p < 0.01. (E) Intracellular
cholesterol level after emodin treatment. Three HCC cell lines were cultured for 48 h in the absence or
presence of 20 µM emodin or 20 µM simvastatin. The values are presented as the mean ± SD of three
independent experiments performed in duplicate; * p < 0.05 and ** p < 0.01.
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2.5. Combination of Emodin and Sorafenib Synergistically Suppresses Cholesterogenic Genes Expression and
Causes Cell Death in HCC Cells
To evaluate the effect of the combination of emodin and sorafenib on cholesterogenic gene
expression, we analyzed HMGCS1, HMGCR, FDPS, DHCR7, and DHCR24 after treatment of HCC cells
with emodin and sorafenib. We observed a synergistic effect of the combination treatment compared
with the single drug treatment on cholesterogenic gene expression in HepG2 and SK-HEP-1 (Figure 5A).
As the intracellular cholesterol levels are balanced by biosynthesis and supplementation from blood
cholesterol [16], the combinatory anti-cancer effect of emodin and sorafenib was tested in the absence
or presence of fetal bovine serum (FBS), which contains large amounts of cholesterol. The viability of
HepG2, SK-HEP-1, and Huh7 cells was rapidly decreased by combination of emodin and sorafenib in
the absence of FBS (Figure 5B). Moreover, we found that supplementation of water-soluble cholesterol
significantly prevented the rapid cell death caused by the combination therapy of emodin and sorafenib
in HCC cells (Figure 5C). These results demonstrated that the suppression of cholesterogenesis is
important for the synergistic anti-cancer efficacy of the combination therapy of emodin and sorafenib.
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Figure 5. Suppression of cholesterol metabolism is required to sensitize HCC cells to the anti-cancer
effect of sorafenib. (A) Cholesterogenic gene expression after the combination treatment of emodin and
sorafenib in HepG2 and SK-HEP-1 cell lines. The cells were incubated with emodin (20 µM), sorafenib
(2 µM), or their combination (20 µM emodin and 2 µM sorafenib) for 24 h. The values represent the
mean ± SEM of three independent experiments performed in duplicate; * p < 0.05, ** p < 0.01, # p < 0.05,
and ## p < 0.01. (B) The cell viability after the combination treatment of emodin and sorafenib in the
absence or presence of 10% fetal bovine serum (FBS). Three cell lines were incubated with 10% FBS
or FBS-free serum for 1 h prior to the combination treatment of emodin and sorafenib. Subsequently,
the cells were incubated for 24 h with the indicated treatments. The values are presented as the
mean ± SEM of three independent experiments performed in triplicate; * p < 0.05, ** p < 0.01, and
# p < 0.05. (C) The cell viability after the combination treatment of emodin and sorafenib in the absence
or presence of water-soluble cholesterol (0.5 mM). Three cell lines were incubated with or without
0.5 mM water-soluble cholesterol for 1 h prior to the combination treatment with emodin and sorafenib.
Subsequently, the cells were incubated for a further 48 h. The values represent the mean ± SEM of
three independent experiments performed in triplicate; * p < 0.05, ** p < 0.01, # p < 0.05, and ## p < 0.01.
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2.6. Emodin Suppressed Oncogenic AKT Signaling Caused by Intracellular Cholesterol Depletion in HCC Cells
Evidence has emerged to indicate that increased lipids and cholesterol, which are correlated with
elevated oncogenic growth signaling, such as PI3K-AKT and MAPK signaling in cancer cells, are
now considered a hallmark of cancer aggressiveness [14,20]. Indeed, many reports have shown that
cholesterol-lowering drugs, such as atorvastatin, lovastatin, and simvastatin, inhibit cancer cell growth
and invasiveness via the suppression of oncogenic signaling in HCC, melanoma, glioma, and ovarian
cancer [21–24]. On this basis, the inhibitory effect of emodin on oncogenic growth signaling in HCC
cells was evaluated. To confirm whether the cholesterol-lowering drug was sufficient to suppress
oncogenic signaling, the phosphorylation of AKT signaling was determined after simvastatin treatment
in HCC cells. AKT signaling was decreased in simvastatin-treated SK-HEP-1 cells in a dose-dependent
manner (Figure 6A), and as shown in Figure 6B, similar to simvastatin, emodin sufficiently inhibited
the phosphorylation of AKT and its downstream signaling cascades, such as 4E-BP1, p70S6K, and
ribosomal protein S6. In addition, the decrease in phosphorylation of AKT by emodin treatment was
partly recovered upon supplementation with cholesterol (Figure 6C), which suggested that cholesterol
depletion mediated the emodin-induced suppression of AKT signaling.
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2.7. Cholesterol-Lowering Effects of Emodin Caused STAT3 Phosphorylation and Associated Expression of Cell
Cycle Regulating Genes in HCC Cells
AKT-mediated oncogenic growth signaling supports tumor growth via the activation of
various transcription factors that regulate the gene expression related to cell cycle progression and
anti-apoptotic properties [25]. Initially, we identified that emodin strongly decreased phosphorylated
STAT3 in HepG2, SK-HEP-1, and PLC/PRF5 cells (Figure 7A); moreover, the synergistic suppression
of STAT3 after the combination of emodin and sorafenib treatment was observed in several HCC cells
(Figure 7B). To validate whether the synergistic effects of emodin on the suppression of phosphorylated
STAT3 was dependent on decreased levels of intracellular cholesterol, the combinatory effect of
simvastatin and sorafenib on STAT3 phosphorylation was analyzed. Similarly, the phosphorylation of
STAT3 was markedly decreased by the combination of simvastatin and sorafenib compared with
the single drug treatment in HepG2 and PLC/PRF5 cells (Figure 7C). As shown in Figure 7D,
cholesterol supplementation partly rescued the decreased STAT3 phosphorylation induced by emodin
and sorafenib in HepG2 cells. As the phosphorylation of STAT3 leads to the transcriptional
activation of gene expression related to cancer aggressiveness [26], the alteration of STAT3 target
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genes after the combination treatment of emodin and sorafenib was measured. Consequently, large
decreases in the expression of STAT3 target genes, such as B-cell lymphoma 2 (BCL-2), survivin,
cyclin D1, vascular endothelial growth factor-A (VEGF-A), basic fibroblast growth factor (bFGF),
matrix metalloproteinase-3 (MMP-3), and matrix metalloproteinase-9 (MMP-9), were observed
in both emodin and sorafenib-treated HepG2 cells (Figure 7E). These results suggested that the
combination of emodin and sorafenib synergistically suppressed the phosphorylation of STAT3 through
a cholesterol-lowering effect.
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Figure 7. The combination treatment of emodin and sorafenib synergistically suppressed STAT3 and
the associated expression of cell cycle-regulating target genes. (A) Emodin inhibits the phosphorylation
of STAT3. Three HCC cell lines were incubated with emodin (10 and 20 µM) for 24 h. (B) The synergistic
effect of the emodin and sorafenib combination on STAT3 phosphorylation. The cells were incubated
with 20 µM of emodin, 2 µM of sorafenib, or their combination (20 µM emodin and 2 µM sorafenib)
for 24 h. (C) Simvastatin increased the suppressive effect of sorafenib on STAT3 phosphorylation.
HepG2 and PLC/PRF5 cells were incubated with 2 µM of sorafenib, 10 µM of simvastatin, or the
combination of sorafenib and simvastatin, as indicated, for 24 h. (D) The supplementation of cholesterol
blocked the downregulation of STAT3 phosphorylation after the combination treatment of emodin
and sorafenib. HepG2 cells were treated with water-soluble cholesterol (0.5 mM) for 1 h prior to the
combination treatment of emodin and sorafenib, and the cells were incubated for a further 24 h. Protein
expression was measured by Western blotting. (E) The combination of emodin and sorafenib decreased
the expression of cell cycle-promoting STAT3 target genes. HepG2 cells were incubated for 24 h with
the combination (20 µM emodin and 2 µM sorafenib). The values represent the mean ± SD of three
independent experiments performed in duplicate; * p < 0.05 and ** p < 0.01.
2.8. Combination Therapy of Emodin and Sorafenib Suppressed Tumor Growth In Vivo
The synergistic anti-cancer effect of the combination of emodin and sorafenib was further
validated in xenografted HepG2 and SK-HEP-1 mice. Tumor volumes were markedly decreased
by the combination treatment of emodin and sorafenib compared with the single treatment with
emodin or sorafenib in HepG2 (Figure 8A) and SK-HEP-1 (Figure 8B) tumors. In addition, increased
cleaved-caspase-3, an apoptotic marker, and decreased phospho-STAT3 were observed in HepG2 (left
panel) and SK-HEP-1 (right panel)-driven tumor tissues treated by the combination of emodin and
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sorafenib (Figure 8C). These results suggested that emodin synergistically enhanced the anti-cancer
efficacy of sorafenib in vivo.
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3. iscussion
The anti-cancer effect of e odin has been reported in several types of cancer; ho ever, the
develop ent of novel therapeutic strategies for cancer treat ent is required [27]. In particular,
various reports have shown that emodin decreases HCC growth through the suppression of oncogenic
growth signaling, such as the MAPK, PI3K-AKT, and STAT3 pathways, in both in vitro and in vivo
models [9,28,29]. Nevertheless, the molecular echanism by which emodin suppresses multiple
oncogenic signaling pathways is poorly understood. In the present study, we demonstrated that
emodin suppressed PI3K-AKT and STAT3 signaling through its cholesterol-lowering effect.
Cholesterol, as an essential co ponent for lipid raft microdomains in the cellular membrane,
is important for cancer growth and aggressiveness and for aintaining oncogenic gro th signaling
through the PI3K- KT and STAT3 pathways [20,30–33]. Experi ental or clinical evidence has
previously sho n that high levels of blood cholesterol accelerate hepatocarcinogenesis and lead
to poor clinical outcomes in patients with HCC [30,31]. Indeed, the anti-cancer and anti- etastatic
effects of cholesterol-lo ering drugs, such as si vastatin, lovastatin, and pitavastatin, hich are
ediated through suppression of the KT and ST T3 path ays, have been sho n in CC, renal
cancer, alignant elano a, and ovarian cancer [22–24,32–34]. Our results show that emodin has
a cholesterol-lowering effect through the suppression of SREBP-2 transcriptional activity and its
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cholesterogenic gene expression in HCC cells. Interestingly, it was demonstrated that fluvastatin,
a member of the statin family, was able to sensitize the anti-cancer efficacy of sorafenib in HCC
cells, which suggested that cholesterol-lowering drugs may be useful for the improvement of clinical
outcomes in patients with advanced HCC who require sorafenib treatment [35]. Similarly, we found
that the supplementation of water-soluble cholesterol significantly blocked the decrease in cell viability,
as well as AKT and STAT3 signaling, upon the combination therapy of emodin and sorafenib. Therefore,
we have proposed that the critical mechanism through which emodin sensitizes HCC cells to the
anti-cancer effects of sorafenib is the suppression of AKT and STAT3 oncogenic growth signaling
caused by decreases in intracellular cholesterol.
Although sorafenib is a molecular targeted therapy used for the standard treatment in patients
with advanced HCC, no significant differences in overall survival have been reported [1,3]. To
overcome the lower efficacy of sorafenib in the treatment of advanced HCC, different types of small
molecules were tested for their suitability as a combination therapy with sorafenib. For example, Chen
et al. [36] reported that 0.5 mg/kg bortezomib synergistically suppressed xenografted PLC/PRF/5
tumors when treated in combination with 5 mg/kg sorafenib by approximately 50% compared with
5 mg/kg sorafenib treatment alone. The sensitizing efficacy of rapamycin (1 mg/kg) in combination
with 50 mg/kg sorafenib on the suppression of xenografted patient-derived HCC has also been
observed [37]. In addition, a selective MEK inhibitor, AZD6244 (25 mg/kg), showed approximately
30–40% greater anti-cancer efficacy with sorafenib (25 mg/kg) compared with the sorafenib-treated
group in patient-derived xenograft models [38]. These previous results suggest that bortezomib,
rapamycin, and AZD6244 could be used to improve sorafenib-based treatment in advanced HCC. It
has become clear that rapamycin-based therapy causes many side effects, including thrombocytopenia,
hyperlipidemia, impaired wound healing, nephrotoxicity, and altered insulin sensitivity [39]. Indeed,
serious side effects, such as anemia (9%), hyperglycemia (10%), lymphopenia (14%), oral mucositis
(11%), and thrombocytopenia (11%), have been observed in clinical trials with the concurrent therapy of
insulin-like growth factor-1 receptor (IGF-1R) inhibitor, cixutumumab, and temsirolimus (a derivative
of rapamycin) in patients with bone or soft-tissue sarcoma [40]. Several side effects associated with
bortezomib, such as fatigue, diarrhea, vomiting, hematological toxicity, and peripheral neuropathy,
have also been reported [41]. In addition, dermatological side effects, such as papulopustular rash,
xerosis, pruritus, hyperpigmentation, and weakness to bacterial infection, were associated with
AZD6244 [42]. However, it was previously reported that 25–40 mg/kg emodin, a higher dosage than
that used in our study, significantly reduced tumor growth in colorectal, prostate, myelocytic leukemia,
and HCC-derived xenografted tumors, with no adverse side effects observed [29,43–45]. In the present
study, we have shown that the combination treatment of emodin (10 mg/kg) and sorafenib (5 mg/kg),
which was lower than previously studied combinations, more effectively reduced tumor growth, by
approximately 50–70% more than the single treatment of sorafenib in HepG2 or SK-HEP-1-transplanted
xenograft models, which suggested that emodin could be clinically applicable for the improved
therapeutic efficacy of sorafenib in advanced HCC without the induction of side effects.
Collectively, our in vitro and in vivo experimental findings indicated that the anti-cancer effect of
emodin was mediated through the suppression of intracellular cholesterol levels, and subsequently
caused the attenuation of oncogenic AKT and STAT3 pathways; in addition, we confirmed that
this would provide a promising therapeutic strategy for improvement of the anti-cancer efficacy of
sorafenib in patients with advanced HCC.
4. Materials and Methods
4.1. Reagents and Antibodies
Emodin, sorafenib, water-soluble cholesterol, doxorubicin, 5-fluorouracil, and simvastatin were
purchased from Sigma Aldrich (St. Louis, MO, USA) and Santa Cruz Biotechnology (Dallas, TX,
USA). Antibodies recognizing phospho-4EBP1T70 (sc-18092), 4EBP1 (CST-9452), phospho-p70S6K1
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(CST-9234), HMGCS1 (CST-36877), HMGCR (ab174830), FDPS (ab189874), AKT (CST-4691),
phospho-AKTS473 (CST-4060), STAT3 (CST-4904), phospho-STAT3 (CST-9145), cleaved-caspase-3
(CST-9664), and β-tubulin (sc-9104) were purchased from Cell Signaling Technology (Danvers, MA,
USA), Santa Cruz Biotechnology, and Abcam (Cambridge, MA, USA).
4.2. Cell Culture and Cell Viability Assay
HCC cell lines (Hep3B, HepG2, SK-HEP-1, Huh7, PLC/PRF5) were obtained from the Korean
Cell Line Bank (Seoul, Korea) and American Type Culture Collection (Manassas, VA, USA) and
cultured in Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute medium
(RPMI1640), and Minimum Essential Medium Eagle alpha medium (MEM-α) supplemented with 10%
fetal bovine serum. To measure cell viability, the cells were seeded into 12- or 24-well tissue culture
dishes and incubated for 24, 48, and 72 h with or without drugs to test the anti-cancer efficacy. After
incubation with the test drugs, the cells were washed and fixed with phosphate-buffered saline (PBS)
and, subsequently, with 4% paraformaldehyde. The cells were stained with 0.5% crystal violet solution
for 20 min at room temperature, the crystal violet-stained cells were solubilized in 1% SDS solution,
and the optical density was measured at 570 nm using an absorbance reader (BioTek, Winooski, VT,
USA) (OD570).
4.3. Western Blotting
For Western blotting, the crude protein samples were extracted from cultured cells using protein
extraction buffer (1% IGEPAL, 150 mM NaCl, 50 mM Tris-HCl (pH 7.9), 10 mM NaF, 0.1 mM
EDTA, and a protease inhibitor cocktail). SDS-PAGE was applied to separate the protein samples
by molecular weight, and the separated proteins were then transferred onto PVDF membranes
(Millipore, Burlington, MA, USA). The membranes with separated proteins were incubated with
primary antibodies (1:1000–1:5000 dilution) and horseradish peroxidase (HRP)-conjugated secondary
antibodies (1:10,000) at 4 ◦C and room temperature, respectively. The Enhanced Chemiluminescence
(ECL) Prime kit (GE Healthcare, Pittsburgh, PA, USA) was used for the analysis of protein expression.
4.4. Quantitative Real-Time PCR
Quantitative real-time PCR was performed as previously described [46]. Briefly, 2 µg of total
RNA extracted from cultured cells by using TRIzol (Invitrogen, Waltham, MA, USA) and cDNA
synthesis was performed by using a high-capacity cDNA reverse transcription kit (Applied Biosystems,
Waltham, MA, USA). Quantitative PCR was performed by using SYBR Green PCR Master Mix (Applied
Biosystems, Waltham, MA, USA). The primer sequences used in the experiment are shown in Table 1.
Table 1. Primer sequences for quantitative real-time PCR.
Gene Forward Primer Reverse Primer
HMGCS1 TGGCAGGGAGTCTTGGTA TCCCACTCCAAATGATGACA
HMGCR GATGGGAGGCCACAAAGAG TTCGGTGGCCTCTAGTGAGA
MVD TTAACTGGTCCTGGTGCAGA AACATCGCGGTCATCAAGTA
FDPS TCCATGATGTCATCTGCCAC AGCCAAGGAAACAGGATG
DHCR7 CTTGAGATGCGGTTCTGTCA TATTTGGCAAGAGGCTGGAG
DHCR24 CTGAAGACAAACCGAGAGGG TGTTGCCAAAGGGGATAATG
BCL-2 CGTACAGTTCCACAAAGGCA ATGTGTGTGGAGAGCGTCAA
Survivin CTTTCTCCGCAGTTTCCTCA TTGGTGAATTTTTGAAACTGGA
Cyclin D1 ATGGAACACCAGCTCCTGTGCTGC TCAGATGTCCACGTCCCGCACGT
VEGFA AGCTGCGCTGATAGACATCC CTACCTCCACCATGCCAAGT
bFGF CCGACGGCCGAGTTGAC TAACGGTTAGCACACACTCCTTTG
MMP-3 ACAAAGGATACAACAGGGACCA GTGAGTGAGTGATAGAGTGGGT
MMP-9 CAGTCCACCCTTGTGCTCTT CCCGAGTGTAACCATAGCGG
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4.5. Tumor Xenograft Assay and Immunohistochemistry
As previously described [46], BALB/c-nude mice were used as human tumor xenograft models.
HepG2 or SK-HEP-1 cells (1 × 106) were harvested and suspended in 100 µL of FBS-free medium.
Then, the cells were innoculated into the flank of mice. Upon reaching a tumor size of 250 mm3, the
mice were intraperitoneally injected with emodin (10 mg/kg), sorafenib (5 mg/kg), a combination of
emodin (10 mg/kg) and sorafenib (5 mg/kg), or vehicle every day for three weeks. The tumor size was
measured using calipers and calculated from the following equation: volume = ab2/2, where a is the
maximal width and b is the maximal orthogonal width. To measure the protein expression determined
by immunohistochemistry, tumor tissues were fixed with 4% paraformaldehyde, embedded in paraffin,
and then divided into sections of 6 µM in thickness. The tissue sections were deparaffinized, rehydrated,
and autoclaved for 10 min in 10 mM sodium citrate (pH 6.0) to retrieve the target antigens. These
sections were then incubated overnight at 4◦C with parimary antibodies such as anti-cleaved-caspase-3
(1:50; CST-9991) and anti-phospho-STAT3 (1:50; CST-9145). The following day, the sections were
incubated with biotinylated secondary antibodies, and finally visualyzed with diaminobenzidine
(DAB). The animal experiments were conducted and managed in accordance with the guidelines of
the Konkuk University Institutional Animal Care and Use Committee (KU16036-1).
4.6. Cell Cycle Analysis
We performed cell cycle analysis following the manufacturer’s instructions (Millipore, Burlington,
MA, USA). Cells were fixed with 70% ethanol under −20 ◦C for 3–5 h. Afterwards, the cells were
reacted with Muse™ cell cycle assay kit reagent (200 µL) for 30 min at room temperature in the dark.
The cell populations were analyzed using a Mini Flow Cytometry Muse™ Cell Analyzer (Millipore,
Burlington, MA, USA).
4.7. Ki67 Cell Proliferation Assay
The Muse™ Ki67 Proliferation Kit was used to measure cell proliferation in accordance with
the supplier’s instructions (Millipore, Burlington, MA, USA). The cells were seeded at a density of
1 × 105 cells/well into a 6-well tissue culture plate and incubated with or without drugs that tested
anti-cancer efficacy. After incubation, the cells were washed with PBS and incubated with fixative
solution for 15 min at room temperature. To increase the permeability of the cell membrane to the
Ki67 antibody, 100 µL of permeabilization solution was reacted with fixed cells for 15 min at room
temperature. To stain the Ki67 protein, used as a marker of cell proliferation, 10 µL Muse™ Hu
Ki67 antibody was incubated with 50 µL of sample for 30 min at room temperature in the dark. The
proliferating cell populations were analyzed using a Mini Flow Cytometry Muse™ Cell Analyzer
(Millipore, Burlington, MA, USA).
4.8. Apoptosis Assays
Annexin-V staining was used to determine the proportion of apoptotic cells in accordance with a
previously described experimental procedure [46]. Briefly, 1× 105 cells/well were seeded onto a 6-well
cell culture plate and incubated with emodin (20 µM), sorafenib (2 µM), or combination of emodin
(20 µM) and sorafenib (2 µM) for 72 h. After drug treatment, the cells were collected into fresh tubes,
washed with cold PBS, and centrifuged at 2000 rpm for 2 min at room temperature. The cell pellets
were incubated in 100 µL Muse™ Annexin V and Dead Cell kit reagents (Millipore, Burlington, MA,
USA) for 20 min at room temperature. The Mini Flow Cytometry Muse™ Cell Analyzer (Millipore,
Burlington, MA, USA) was applied for the measurement of the apoptotic cell numbers.
Int. J. Mol. Sci. 2018, 19, 3127 14 of 17
4.9. Measurement of Intracellular Cholesterol
We measured the total cellular cholesterol using the Amplex Red cholesterol assay kit (Invitrogen,
Waltham, MA, USA) in accordance with the manufacturer’s protocols. Briefly, prepared cultured cells
were harvested and kept at −70 ◦C. The frozen cells were incubated with reaction buffer for 30 min
on ice, and then sonicated to disrupt the cellular membrane. Samples (50 µL) were mixed with equal
volume of Amplex Red reagent containing HRP, cholesterol oxidase, and cholesterol esterase, and
then the mixture was reacted for 30 min at 37 ◦C. The fluorescence intensity was measured using a
fluorescence microplate reader (BioTek, Winooski, VT, USA) at ex/em = 530/590. The cholesterol
levels were normalized using protein concentration determined by Bradford assay.
4.10. Luciferase Assay
The steroid responsive element (SRE)-wild type (WT) or -mutant (Mut) containing luciferase
vector (pSynSRE-T-Luc and pSynSRE-Mut-T-Luc) was transfected into SK-HEP-1 cells using
Lipofectamine 2000 (Invitrogen, Waltham, MA, USA). pSynSRE-T-Luc (Addgene plasmid #60444) and
pSynSRE-Mut-T-Luc (Addgene plasmid #60490) were gifts from Timothy Osborne [47]. Luciferase
activities were analyzed using a Synergy 2 Luminometer (BioTek, Winooski, VT, USA) and normalized
against the activity of β-galactose.
4.11. Statistical Analysis
All statistical analyses were performed using the unpaired Student’s t-test and one-way analysis
of variance (ANOVA) with Tukey post hoc test; the data are presented as the mean ± standard
deviation (SD). For combination studies with emodin and sorafenib in cell-based experiments and
mouse xenografts, the two-way ANOVA with Tukey post hoc test was performed, and the data are
represented as the mean ± standard error of the mean (SEM) [48]. A p value of less than 0.05 was
considered statistically significant.
5. Conclusions
The major findings of this study are that emodin synergistically increases anticancer efficacy
of sorafenib through suppression of oncogenic growth signaling and STAT3-mediated cell cycle
progression and proliferation by attenuating cholesterol biosynthesis in vitro and in vivo. Overall,
these results suggested that the combination of emodin and sorafenib may be potentially therapeutic
for patients with advanced HCC.
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